Cabot Corporation
CBTBasic MaterialsNASDAQSpecialty Chemicals
Scan Results
Daily timeframePart of the basic materials sector, Cabot Corporation (CBT) is listed under Specialty Chemicals. Valued at $4.21B, CBT is a mid-cap name in its sector. It operates through two segments, Reinforcement Materials and Performance Chemicals.
Market Cap
$4.21B
Beta
0.83
P/E (TTM)
22.82
P/E (Fwd)
11.66
EPS (TTM)
$3.57
EPS (Fwd)
$6.99
ROE
13.4%
ROA
8.9%
Cash
$250.0M
Total Debt
$1.29B
Free CF
$258.3M
52W Change
1.3%
Annual Financials
Cash vs Debt
Where CBT stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CBT finished 0.86% above its 150-day moving average ($79.96) and 5.56% above its 200-day moving average ($76.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBT overbought or oversold?
At the September 2, 2026 close, CBT's RSI(14) was 29.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CBT has $250.0M in cash with $1.29B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $258.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 13.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $4.32B (2022) to $3.71B (2025), a 14% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CBT.